|
1
|
Bartels DW, Davidson MH and Gong WC: Type
2 diabetes and cardiovascular disease: reducing the risk. J Manag
Care Pharm. 13:S2–S15. 2007.PubMed/NCBI
|
|
2
|
Bakker W, Eringa EC, Sipkema P and van
Hinsbergh VW: Endothelial dysfunction and diabetes: roles of
hyperglycemia, impaired insulin signaling and obesity. Cell Tissue
Res. 335:165–189. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lebovitz HE: Insulin resistance – a common
link between type 2 diabetes and cardiovascular disease. Diabetes
Obes Metab. 8:237–249. 2006.
|
|
4
|
Kowalska I: Role of adipose tissue in the
development of vascular complications in type 2 diabetes mellitus.
Diabetes Res Clin Pract. 78:14–22. 2007. View Article : Google Scholar
|
|
5
|
Kadowaki T, Yamauchi T, Kubota N, Hara K,
Ueki K and Tobe K: Adiponectin and adiponectin receptors in insulin
resistance, diabetes, and the metabolic syndrome. J Clin Invest.
116:1784–1792. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yanagawa T, Taniguchi A, Fukushima M,
Nakai Y, Nagasaka S, Ohgushi M, Matsumoto K, Kuroe A, Ohya M and
Seino Y: Leptin, triglycerides, and interleukin 6 are independently
associated with C-reactive protein in Japanese type 2 diabetic
patients. Diabetes Res Clin Pract. 75:2–6. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rabe K, Lehrke M, Parhofer KG and Broedl
UC: Adipokines and insulin resistance. Mol Med. 14:741–751. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gulcelik NE, Usman A and Gürlek A: Role of
adipocytokines in predicting the development of diabetes and its
late complications. Endocrine. 36:397–403. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gualillo O, González-Juanatey JR and Lago
F: The emerging role of adipokines as mediators of cardiovascular
function: physiologic and clinical perspectives. Trends Cardiovasc
Med. 17:275–283. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Snehalatha C, Mukesh B, Simon M,
Viswanathan V, Haffner SM and Ramachandran A: Plasma adiponectin is
an independent predictor of type 2 diabetes in Asian indians.
Diabetes Care. 26:3226–3229. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li S, Shin HJ, Ding EL and van Dam RM:
Adiponectin levels and risk of type 2 diabetes: a systematic review
and meta-analysis. JAMA. 302:179–188. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lautamäki R, Rönnemaa T, Huupponen R,
Lehtimäki T, Iozzo P, Airaksinen KE, Knuuti J and Nuutila P: Low
serum adiponectin is associated with high circulating oxidized
low-density lipo-protein in patients with type 2 diabetes mellitus
and coronary artery disease. Metabolism. 56:881–886.
2007.PubMed/NCBI
|
|
13
|
Jaleel F, Jaleel A, Aftab J and Rahman MA:
Relationship between adiponectin, glycemic control and blood lipids
in diabetic type 2 postmenopausal women with and without
complication of ischemic heart disease. Clin Chim Acta. 370:76–81.
2006. View Article : Google Scholar
|
|
14
|
Hotta K, Funahashi T, Arita Y, Takahashi
M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K,
et al: Plasma concentrations of a novel, adipose-specific protein,
adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc
Biol. 20:1595–1599. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vergès B, Petit JM, Duvillard L, Dautin G,
Florentin E, Galland F and Gambert P: Adiponectin is an important
determinant of apoA-I catabolism. Arterioscler Thromb Vasc Biol.
26:1364–1369. 2006.
|
|
16
|
Han R, Lai R, Ding Q, Wang Z, Luo X, Zhang
Y, Cui G, He J, Liu W and Chen Y: Apolipoprotein A-I stimulates
AMP-activated protein kinase and improves glucose metabolism.
Diabetologia. 50:1960–1968. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schulze MB, Shai I, Rimm EB, Li T, Rifai N
and Hu FB: Adiponectin and future coronary heart disease events
among men with type 2 diabetes. Diabetes. 54:534–539. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Krakoff J, Funahashi T, Stehouwer CD,
Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson
RL, Knowler WC and Lindsay RS: Inflammatory markers, adiponectin,
and risk of type 2 diabetes in the Pima Indian. Diabetes Care.
26:1745–51. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yuan G, Zhou L, Tang J, Yang Y, Gu W, Li
F, Hong J, Gu Y, Li X, Ning G and Chen M: Serum CRP levels are
equally elevated in newly diagnosed type 2 diabetes and impaired
glucose tolerance and related to adiponectin levels and insulin
sensitivity. Diabetes Res Clin Pract. 72:244–250. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wannamethee SG, Tchernova J, Whincup P,
Lowe GD, Kelly A, Rumley A, Wallace AM and Sattar N: Plasma leptin:
associations with metabolic, inflammatory and haemostatic risk
factors for cardiovascular disease. Atherosclerosis. 191:418–426.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Reilly MP, Iqbal N, Schutta M, Wolfe ML,
Scally M, Localio AR, Rader DJ and Kimmel SE: Plasma leptin levels
are associated with coronary atherosclerosis in type 2 diabetes. J
Clin Endocrinol Metab. 89:3872–3878. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stefanović A, Kotur-Stevuljević J, Spasić
S, Bogavac-Stanojević N and Bujisić N: The influence of obesity on
the oxidative stress status and the concentration of leptin in type
2 diabetes mellitus patients. Diabetes Res Clin Pract. 79:156–163.
2008.PubMed/NCBI
|
|
23
|
Abdella NA, Mojiminiyi OA, Moussa MA, Zaki
M, Al Mohammedi H, Al Ozairi ES and Al Jebely S: Plasma leptin
concentration in patients with type 2 diabetes: relationship to
cardiovascular disease risk factors and insulin resistance. Diabet
Med. 22:278–285. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Asakawa H, Tokunaga K and Kawakami F:
Relationship of leptin level with metabolic disorders and
hypertension in Japanese type 2 diabetes mellitus patients. J
Diabetes Complications. 15:57–62. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thorand B, Zierer A, Baumert J, Meisinger
C, Herder C and Koenig W: Associations between leptin and the
leptin/adiponectin ratio and incident type 2 diabetes in
middle-aged men and women: results from the MONICA/KORA Augsburg
study 1984–2002. Diabet Med. 27:1004–1011. 2010.PubMed/NCBI
|
|
26
|
Maenhaut N and van de Voorde J: Regulation
of vascular tone by adipocytes. BMC Med. 16:9–25. 2011.
|
|
27
|
Oda N, Imamura S, Fujita T, Uchida Y,
Inagaki K, Kakizawa H, Hayakawa N, Suzuki A, Takeda J, Horikawa Y
and Itoh M: The ratio of leptin to adiponectin can be used as an
index of insulin resistance. Metabolism. 57:268–273. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu HL, Wang HW, Wen Y, Zhang MX and Lin
HH: Roles of adipocyte derived hormone adiponectin and resistin in
insulin resistance of type 2 diabetes. World J Gastroenterol.
12:1747–1751. 2006.PubMed/NCBI
|
|
29
|
Mojiminiyi OA and Abdella NA: Associations
of resistin with inflammation and insulin resistance in patients
with type 2 diabetes mellitus. Scand J Clin Lab Invest. 67:215–225.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kusminski CM, McTernan PG and Kumar S:
Role of resistin in obesity, insulin resistance and Type II
diabetes. Clin Sci (Lond). 109:243–256. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tokuyama Y, Osawa H, Ishizuka T, Onuma H,
Matsui K, Egashira T, Makino H and Kanatsuka A: Serum resistin
level is associated with insulin sensitivity in Japanese patients
with type 2 diabetes mellitus. Metabolism. 56:693–698. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takata Y, Osawa H, Kurata M, Kurokawa M,
Yamauchi J, Ochi M, Nishida W, Okura T, Higaki J and Makino H:
Hyperresistinemia is associated with coexistence of hypertension
and type 2 diabetes. Hypertension. 5:534–539. 2008. View Article : Google Scholar
|
|
33
|
de Luis DA, Sagrado MG, Conde R, Aller R,
Izaola O, de la Fuente B, Castrillón JL and Romero E: Relation of
resistin levels with cardiovascular risk factors, insulin
resistance and inflammation in naïve diabetes obese patients.
Diabetes Res Clin Pract. 89:110–114. 2010.PubMed/NCBI
|
|
34
|
Al-Daghri N, Chetty R, McTernan PG,
Al-Rubean K, Al-Attas O, Jones AF and Kumar S: Serum resistin is
associated with C-reactive protein and LDL cholesterol in type 2
diabetes and coronary artery disease in a Saudi population.
Cardiovasc Diabetol. 4:1–6. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lau CH and Muniandy S: Novel
adiponectin-resistin (AR) and insulin resistance (IRAR) indexes are
useful integrated diagnostic biomarkers for insulin resistance,
type 2 diabetes and metabolic syndrome: a case control study.
Cardiovasc Diabetol. 10:82011. View Article : Google Scholar
|
|
36
|
Esteghamati A, Alamdari A, Zandieh A,
Elahi S, Khalilzadeh O, Nakhjavani M and Meysamie A: Serum visfatin
is associated with type 2 diabetes mellitus independent of insulin
resistance and obesity. Diabetes Res Clin Pract. 91:154–158. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Alghasham AA and Barakat YA: Serum
visfatin and its relation to insulin resistance and inflammation in
type 2 diabetic patients with and without macroangiopathy. Saudi
Med J. 29:185–192. 2008.PubMed/NCBI
|
|
38
|
Chang YH, Chang DM, Lin KC, Shin SJ and
Lee YJ: Visfatin in overweight/obesity, type 2 diabetes mellitus,
insulin resistance, metabolic syndrome and cardiovascular diseases:
a meta-analysis and systemic review. Diabetes Metab Res Rev.
27:515–527. 2011. View Article : Google Scholar
|
|
39
|
El-Mesallamy HO, Kassem DH, El-Demerdash E
and Amin AI: Vaspin and visfatin/Nampt are interesting interrelated
adipokines playing a role in the pathogenesis of type 2 diabetes
mellitus. Metabolism. 60:63–70. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sandeep S, Velmurugan K, Deepa R and Mohan
V: Serum visfatin in relation to visceral fat, obesity, and type 2
diabetes mellitus in Asian Indians. Metabolism. 56:565–570. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shaker O, El-Shehaby A, Zakaria A, Mostafa
N, Talaat S, Katsiki N and Mikhailidis DP: Plasma visfatin and
retinol binding protein-4 levels in patients with type 2 diabetes
mellitus and their relationship to adiposity and fatty liver. Clin
Biochem. 44:1457–1463. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen MP, Chung FM, Chang DM, Tsai JC,
Huang HF, Shin SJ and Lee YJ: Elevated plasma level of
visfatin/pre-B cell colony-enhancing factor in patients with type 2
diabetes mellitus. J Clin Endocrinol Metab. 91:295–299. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pereira EC, Ferderbar S, Bertolami MC,
Faludi AA, Monte O, Xavier HT, Pereira TV and Abdalla DS:
Biomarkers of oxidative stress and endothelial dysfunction in
glucose intolerance and diabetes mellitus. Clin Biochem.
41:1454–1460. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Krzyzanowska K, Mittermayer F, Wolzt M and
Schernthaner G: ADMA, cardiovascular disease and diabetes. Diabetes
Res Clin Pract. 15:122–126. 2008. View Article : Google Scholar
|
|
45
|
Kanazawa I, Yano S, Notsu Y, Yamaguchi T,
Nabika T and Sugimoto T: Asymmetric dimethylarginine as a risk
factor for cardiovascular disease in Japanese patients with type 2
diabetes mellitus. Clin Endocrinol (Oxf). 74:467–472. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yasuda S, Miyazaki S, Kanda M, Goto Y,
Suzuki M, Harano Y and Nonogi H: Intensive treatment of risk
factors in patients with type-2 diabetes mellitus is associated
with improvement of endothelial function coupled with a reduction
in the levels of plasma asymmetric dimethylarginine and endogenous
inhibitor of nitric oxide synthase. Eur Heart J. 27:1159–1165.
2006.
|
|
47
|
de Luis DA, Fernandez N, Arranz ML, Aller
R, Izaola O and Romero E: Total homocysteine levels relation with
chronic complications of diabetes, body composition, and other
cardiovascular risk factors in a population of patients with
diabetes mellitus type 2. J Diabetes Complications. 19:42–46.
2005.PubMed/NCBI
|
|
48
|
Akalin A, Alatas O and Colak O: Relation
of plasma homocysteine levels to atherosclerotic vascular disease
and inflammation markers in type 2 diabetic patients. Eur J
Endocrinol. 158:47–52. 2008. View Article : Google Scholar
|
|
49
|
Wang Z, Pini M, Yao T, Zhou Z, Sun C,
Fantuzzi G and Song Z: Homocysteine suppresses lipolysis in
adipocytes by activating the AMPK pathway. Am J Physiol Endocrinol
Metab. 301:703–712. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li Y, Jiang C, Xu G, Wang N, Zhu Y, Tang C
and Wang X: Homocysteine upregulates resistin production from
adipocytes in vivo and in vitro. Diabetes. 57:817–827. 2008.
View Article : Google Scholar : PubMed/NCBI
|
